Skip to main content

Equillium, Inc.

corporate_fare Company Profile

Equillium, Inc.

EQ·NASDAQ·Life Sciences·CIK 0001746466

We are a biotechnology company focused on developing new treatments for severe autoimmune and inflammatory disorders. Our main goal is to advance EQ504, a new aryl hydrocarbon receptor (AhR) modulator, through clinical development. EQ504 is in the preclinical stage and has shown therapeutic benefits in various models by increasing anti-inflammatory cells and cytokines, reducing pro-inflammatory cells and cytokines, and improving intestinal tissue barrier function and repair. We initially plan to develop EQ504 for ulcerative colitis (UC) and other gastrointestinal (GI) diseases, with potential future expansion into inflammatory lung diseases. We also have EQ302, a preclinical-stage, first-in-class, selective, bi-specific inhibitor of IL-15 and IL-21, designed for oral delivery. Inhibiting IL-15 and IL-21 is considered a potential treatment for certain GI conditions, including celiac disease. We have conducted preclinical development for EQ302, including in vivo pharmacology studies and formulation development, and are evaluating its further advancement, including manufacturing and toxicology studies to support a potential investigational new drug (IND) filing and a first-in-human clinical study. Our pipeline of therapeutic candidates aims to address unmet medical needs in gastroenterology, dermatology, and pulmonology. Our strategy includes completing the preclinical and clinical development of EQ504 and evaluating the further advancement of EQ302. We intend to start a Phase 1 proof-of-mechanism study for EQ504 in mid-2026, with data expected approximately six months later.

Equillium, Inc. (NASDAQ:EQ) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 19 items for EQ at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 19 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for EQ spans 8-K, 10-Q, 4, 144.

Recent high-impact activity:

  • Equillium Beats Q3 Estimates, Cash Runway Extended Into 2029
  • Equillium Closes $20M Milestone Tranche After First EQ504 Patient Dosed
  • First Patient Dosed in EQ504 Phase 1, Unlocking $20M Milestone Tranche
  • Equillium Secures Clearance to Launch Phase 1 Trial of EQ504, with Dosing Expected by Early November
  • Equillium Cleared to Start First-in-Human Trial of EQ504 in Australia

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$22.4M
Diluted EPS
-$0.39
Op. Cash Flow
-$22.75M
Free Cash Flow
-$22.79M
Operating Income
-$23.63M
Cash & Equivalents
$30.28M
Debt / Equity
0.00×
Shares Outstanding
61.46M sh
Source: 10-K · filed 2026-03-25 · accession 0001193125-26-124143

Short Interest & Short Volume

9.52 days to cover

FINRA reported short interest of 5,923,382 shares in EQ as of the October 30, 2026 settlement, a 4.7% increase from the prior period — about 9.5 days to cover at its recent average daily volume. On November 20, 2026, 16.4% of EQ volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)5,923,382 shares as of October 30, 2026
Change vs prior period▲ 4.7%
Days to cover9.52 at avg daily volume of 622,382
Daily short volume (FINRA facilities)16.4% of 449,104 shares on November 20, 2026
5-day average short volume15.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for EQ, detected from its recent SEC filings.

1 shelf registration

35.1M Shares Registered for Resale · No Proceeds to the Company

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with E →
$1.02 -3.77% today
52-week range · as of 2026-10-26 $0.7562 – $3.54
Market cap
$87.26M
Volume
570.8K (1.2× avg)
3-mo avg 471.8K
Live data · 2026-11-22 09:18 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed EQ - Latest Insights

EQ
Nov 12, 2026, 4:20 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $1.34
Real-time Price: $1.02 info
Change: -$0.320 (-24%) info
Market Cap: $87.264M info
EQ
Oct 26, 2026, 5:09 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.29
Real-time Price: $1.02 info
Change: -$0.270 (-21%) info
Market Cap: $87.264M info
EQ
Oct 26, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.12
Real-time Price: $1.02 info
Change: -$0.1003 (-9%) info
Market Cap: $87.264M info
EQ
Oct 05, 2026, 5:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.42
Real-time Price: $1.02 info
Change: -$0.400 (-28%) info
Market Cap: $87.264M info
EQ
Oct 05, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.51
Real-time Price: $1.02 info
Change: -$0.490 (-32%) info
Market Cap: $87.264M info
EQ
Aug 13, 2026, 4:20 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $2.01
Real-time Price: $1.02 info
Change: -$0.9886 (-49%) info
Market Cap: $87.264M info
EQ
Aug 13, 2026, 4:15 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $2.04
Real-time Price: $1.02 info
Change: -$1.02 (-50%) info
Market Cap: $87.264M info
EQ
Jun 05, 2026, 4:42 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $2.94
Real-time Price: $1.02 info
Change: -$1.92 (-65%) info
Market Cap: $87.264M info
EQ
Jun 04, 2026, 5:30 PM EDT
Filing Type: 144
Importance Score:
8
Price at Filing: $3.16
Real-time Price: $1.02 info
Change: -$2.14 (-68%) info
Market Cap: $87.264M info
EQ
May 29, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $2.90
Real-time Price: $1.02 info
Change: -$1.88 (-65%) info
Market Cap: $87.264M info
EQ
May 13, 2026, 4:10 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $2.27
Real-time Price: $1.02 info
Change: -$1.25 (-55%) info
Market Cap: $87.264M info
EQ
May 13, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.31
Real-time Price: $1.02 info
Change: -$1.29 (-56%) info
Market Cap: $87.264M info
EQ
May 13, 2026, 4:01 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $2.31
Real-time Price: $1.02 info
Change: -$1.29 (-56%) info
Market Cap: $87.264M info
EQ
Apr 15, 2026, 9:00 AM EDT
Filing Type: DEF 14A
Importance Score:
9
Price at Filing: $1.90
Real-time Price: $1.02 info
Change: -$0.8801 (-46%) info
Market Cap: $87.264M info
EQ
Apr 07, 2026, 5:13 PM EDT
Filing Type: S-3
Importance Score:
7
Price at Filing: $1.92
Real-time Price: $1.02 info
Change: -$0.900 (-47%) info
Market Cap: $87.264M info
EQ
Mar 25, 2026, 4:15 PM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $2.06
Real-time Price: $1.02 info
Change: -$1.04 (-50%) info
Market Cap: $87.264M info
EQ
Mar 25, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.06
Real-time Price: $1.02 info
Change: -$1.04 (-50%) info
Market Cap: $87.264M info
EQ
Mar 25, 2026, 4:05 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $2.06
Real-time Price: $1.02 info
Change: -$1.04 (-50%) info
Market Cap: $87.264M info
EQ
Mar 13, 2026, 8:15 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.20
Real-time Price: $1.02 info
Change: -$1.18 (-54%) info
Market Cap: $87.264M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets